EDINBURGH, Scotland, March 19,
2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC
BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage
biotechnology company developing platform allogeneic gamma-delta T
cell therapies for cancer and other indications, today announced
that it has adjourned its General Meeting of the Company to a later
date.
TC BioPharm is awaiting clarity on additional information of a
material matter related to the shareholder vote. The Company
was previously scheduled to vote on two outstanding
resolutions.
Ordinary Resolution 1: THAT the chairman of the
General Meeting be and is hereby authorized (in his/her sole
discretion) to adjourn the General Meeting to a later date or dates
(and on more than one occasion), if necessary, to permit further
solicitation of proxies if, at the time of the General Meeting,
there are insufficient persons present in person and/or by proxy at
the General Meeting to pass Ordinary Resolution 2 in accordance
with the quorum requirements of the Nasdaq Marketplace Rules;
Ordinary Resolution 2: THAT: Without prejudice to
any existing authorities, the issuance of securities in one or more
non-public offerings be approved in accordance with Nasdaq
Marketplace Rule 5635(d).
"Management would like to thank and acknowledge the ongoing
support of our shareholder base for its participation and support
of the company," said Bryan Kobel,
CEO of TC BioPharm. "We look forward to executing on our
strategic business plan and capitalizing on the milestones that lay
ahead."
The record date for the stockholders to vote at the
Extraordinary General Meeting remains the close of business
on March 11, 2024 (the "Record Date"). Stockholders who have
previously submitted their proxy or otherwise voted and who do not
want to change their vote need not take any action –
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding the Company's intent or ability to effect any budget
savings or execute on any M&A or capital raising strategy.
These statements are based on management's current assumptions and
are neither promises nor guarantees, but involve known and unknown
risks, uncertainties and other important factors that may cause the
Company's actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements, including that the proposed issuance of shares may not
be approved by the Company's shareholders. For other important
factors that could cause actual results to differ materially from
the forward-looking statements in this press release, please see
the risks and uncertainties identified under the heading "Risk
Factors" in our Annual Report on Form 20-F for the year ended
December 31, 2022, and our other
reports filed with the SEC, all of which is available on the
Company's Investor Relations website at www.tcbiopharm.com and on
the SEC website at www.sec.gov. All forward-looking statements
reflect the Company's beliefs and assumptions only as of the date
of this press release. The Company undertakes no obligation to
update forward-looking statements to reflect future events or
circumstances.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
gamma-delta T cell therapies for the treatment of cancer with human
efficacy data in acute myeloid leukemia. Gamma-delta T cells are
naturally occurring immune cells that embody properties of both the
innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of
acute myeloid leukemia using the Company's proprietary allogeneic
CryoTC technology to provide frozen product to clinics
worldwide.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tcbp-adjourns-general-meeting-until-a-later-date-302092505.html
SOURCE TC BioPharm